Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -518.88M | -559.78M | -644.76M | -715.54M | -649.13M |
| Total Depreciation and Amortization | 78.36M | 84.04M | 83.70M | 77.17M | 63.33M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.02M | 143.05M | 175.56M | 196.91M | 176.45M |
| Change in Net Operating Assets | -41.98M | 11.74M | 13.69M | 296.00K | 26.33M |
| Cash from Operations | -350.48M | -320.95M | -371.81M | -441.17M | -383.03M |
| Capital Expenditure | -1.79M | -4.90M | -6.47M | -6.52M | -10.84M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 277.10M | 277.10M |
| Divestitures | 0.00 | 0.00 | -4.44M | -4.44M | -4.44M |
| Other Investing Activities | -4.30M | -5.04M | -5.96M | -6.31M | -4.01M |
| Cash from Investing | -6.09M | -9.94M | -16.87M | 259.83M | 257.82M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.75M | -8.59M | -8.43M | -8.36M | -8.52M |
| Issuance of Common Stock | 387.64M | 487.64M | 528.66M | 407.23M | 172.51M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -278.00K | -1.52M | 1.29M | 1.29M | 1.29M |
| Cash from Financing | 378.61M | 477.54M | 521.53M | 400.17M | 165.29M |
| Foreign Exchange rate Adjustments | 937.00K | 9.38M | 18.04M | 12.49M | 11.02M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 22.98M | 156.02M | 150.90M | 231.31M | 51.09M |